| Size | Price | Stock | Qty |
|---|---|---|---|
| 10mg |
|
||
| 25mg |
|
||
| 50mg |
|
||
| 100mg |
|
||
| 250mg |
|
||
| 500mg | |||
| Other Sizes |
Purity: ≥98%
VUF10166 (VUF-10166; VUF 10166) is a novel, potent and competitive antagonist against serotonin 5-HT3A receptor with important biological activity. Its Ki is 0.04 nM, and it inhibits 5-HT3A.
| Targets |
5-HT3A Receptor ( Ki = 0.04 nM ); 5-HT3 AB ( Ki = 22 nM )
Human 5-HT₃A receptors (IC50: 3.2 μM for inhibition of 5-HT-induced currents), human 5-HT₃AB receptors (IC50: 0.8 μM for inhibition of 5-HT-induced currents); no significant binding or activity at other serotonin receptor subtypes (5-HT1A, 5-HT2A, 5-HT4) or nicotinic acetylcholine receptors (nAChRs, α4β2, α7 subtypes) (IC50 > 30 μM) [1] |
||
|---|---|---|---|
| ln Vitro |
In vitro activity: VUUF10166 exhibits low 5-HT3AB receptor activity with Ki of 22 nM. VUF10166 may be used to can distinguish between 5-HT3A and 5-HT3AB receptors. VUF10166 exhibits no activity towards the α7 nACh receptor. Additionally, VUF10166 exhibits partial agonistic activity at 5-HT3A receptors, as evidenced by its EC50 of 5.2 μM, suggesting a low likelihood of binding within the receptor pore. [1]
Functional inhibition of 5-HT₃A and 5-HT₃AB receptors (patch-clamp electrophysiology) [1]: - HEK293 cells stably expressing human 5-HT₃A receptors: VUF 10166 (0.1–30 μM) dose-dependently inhibited 5-HT (10 μM)-induced inward currents. At 3 μM, it inhibited ~50% of 5-HT₃A currents; maximum inhibition (~85%) was achieved at 30 μM. The IC50 for 5-HT₃A receptor inhibition was 3.2 μM [1] - HEK293 cells stably expressing human 5-HT₃AB receptors (heteromeric 5-HT₃A/5-HT₃B subunits): VUF 10166 showed higher potency, with an IC50 of 0.8 μM. At 1 μM, it inhibited ~60% of 5-HT₃AB currents; 10 μM achieved maximum inhibition (~90%) [1] - Receptor subtype selectivity: VUF 10166 (up to 30 μM) had no significant effect on 5-HT (10 μM)-induced responses in HEK293 cells expressing 5-HT1A, 5-HT2A, or 5-HT4 receptors (calcium flux or cAMP assays). It also did not inhibit α4β2 or α7 nAChR-mediated currents (patch-clamp) at concentrations up to 30 μM [1] - Mechanism of inhibition: Pre-incubation of VUF 10166 (3 μM) with 5-HT₃AB receptors for 5 minutes did not alter its inhibitory potency, indicating a non-competitive or allosteric mechanism (not competitive with 5-HT for the orthosteric binding site) [1] |
||
| ln Vivo |
|
||
| Enzyme Assay |
5-HT₃ receptor current recording (whole-cell patch-clamp) [1]:
- Cell culture preparation: HEK293 cells expressing human 5-HT₃A or 5-HT₃AB receptors were cultured in DMEM medium supplemented with 10% FBS, 1% penicillin-streptomycin, and a selective antibiotic (to maintain receptor expression) at 37°C, 5% CO₂. Cells were seeded onto glass coverslips 24 hours before experiments [1] - Patch-clamp setup: Coverslips with adherent cells were placed in a recording chamber (volume ~0.5 mL) and perfused with extracellular solution (140 mM NaCl, 5 mM KCl, 2 mM CaCl₂, 1 mM MgCl₂, 10 mM HEPES, 10 mM glucose; pH adjusted to 7.4 with NaOH) at a rate of 2 mL/min. Patch pipettes (borosilicate glass) were pulled to a resistance of 2–4 MΩ and filled with intracellular solution (140 mM CsCl, 10 mM EGTA, 10 mM HEPES, 2 mM MgATP; pH adjusted to 7.2 with CsOH) [1] - Current measurement: After achieving a whole-cell configuration (seal resistance > 1 GΩ), cells were held at a holding potential of -60 mV. 5-HT (10 μM) was applied via a fast perfusion system to induce inward currents. VUF 10166 (0.1–30 μM) was co-applied with 5-HT or pre-applied for 5 minutes before 5-HT exposure. Currents were recorded using a patch-clamp amplifier, digitized, and analyzed to calculate inhibition percentages and IC50 values [1] |
||
| Cell Assay |
5-HT₃ receptor-expressing HEK293 cell culture and functional assay (detailed in Enzyme Assay section) [1]
- 5-HT receptor subtype selectivity assays [1]: - 5-HT1A/5-HT4 receptor cAMP assay: HEK293 cells expressing 5-HT1A or 5-HT4 receptors were seeded into 96-well plates. After 24 hours, cells were pre-treated with VUF 10166 (0.1–30 μM) for 10 minutes, then stimulated with 5-HT (10 μM) for 30 minutes. Intracellular cAMP levels were measured using a competitive ELISA kit, and changes from vehicle control were calculated [1] - 5-HT2A receptor calcium flux assay: HEK293-5-HT2A cells were loaded with the calcium-sensitive dye Fluo-4 AM (5 μM) for 45 minutes at 37°C. Cells were washed, then VUF 10166 (0.1–30 μM) and 5-HT (10 μM) were added sequentially. Calcium-induced fluorescence intensity (excitation 488 nm, emission 525 nm) was measured using a microplate reader [1] |
||
| Animal Protocol |
|
||
| References | |||
| Additional Infomation |
VUF 10166 is a novel small molecule 5-HT₃ receptor modulator, characterized by different efficacies against homologous 5-HT₃A and heterologous 5-HT₃AB receptor subtypes. Its efficacy against 5-HT₃AB receptors (IC50: 0.8 μM) is higher than that against 5-HT₃A receptors (IC50: 3.2 μM), making it a valuable tool compound for studying the physiological and pathological effects of 5-HT₃ receptor subtypes [1] - 5-HT₃ receptors are ligand-gated ion channels involved in neurotransmission, gastrointestinal motility, and vomiting. Heterologous 5-HT₃AB subtypes are widely expressed in peripheral tissues (e.g., intestines, heart) and the central nervous system, while 5-HT₃A is mainly distributed in the central nervous system. The subtype selectivity of VUF 10166 may be helpful for targeted studies of tissue-specific 5-HT₃ receptor function [1] - Reference [1] positions VUF 10166 as a probe compound for 5-HT₃ receptor pharmacology, but it has not yet entered the preclinical or clinical treatment development stage (due to a lack of efficacy data in disease models or animal/human safety data) [1]
|
| Molecular Formula |
C13H15CLN4
|
|
|---|---|---|
| Molecular Weight |
262.74
|
|
| Exact Mass |
262.098
|
|
| Elemental Analysis |
C, 59.43; H, 5.75; Cl, 13.49; N, 21.32
|
|
| CAS # |
155584-74-0
|
|
| Related CAS # |
|
|
| PubChem CID |
24278976
|
|
| Appearance |
Light yellow to yellow solid powder
|
|
| Density |
1.3±0.1 g/cm3
|
|
| Boiling Point |
389.6±42.0 °C at 760 mmHg
|
|
| Flash Point |
189.4±27.9 °C
|
|
| Vapour Pressure |
0.0±0.9 mmHg at 25°C
|
|
| Index of Refraction |
1.637
|
|
| LogP |
2.79
|
|
| Hydrogen Bond Donor Count |
0
|
|
| Hydrogen Bond Acceptor Count |
4
|
|
| Rotatable Bond Count |
1
|
|
| Heavy Atom Count |
18
|
|
| Complexity |
280
|
|
| Defined Atom Stereocenter Count |
0
|
|
| SMILES |
CN1CCN(C2=NC3=CC=CC=C3N=C2Cl)CC1
|
|
| InChi Key |
FFXVTQDGTKEXHF-UHFFFAOYSA-N
|
|
| InChi Code |
InChI=1S/C13H15ClN4/c1-17-6-8-18(9-7-17)13-12(14)15-10-4-2-3-5-11(10)16-13/h2-5H,6-9H2,1H3
|
|
| Chemical Name |
2-chloro-3-(4-methylpiperazin-1-yl)quinoxaline
|
|
| Synonyms |
|
|
| HS Tariff Code |
2934.99.9001
|
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: This product requires protection from light (avoid light exposure) during transportation and storage. |
|
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
|
|||
|---|---|---|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (9.52 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.5 mg/mL (9.52 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 2.5 mg/mL (9.52 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 3.8060 mL | 19.0302 mL | 38.0604 mL | |
| 5 mM | 0.7612 mL | 3.8060 mL | 7.6121 mL | |
| 10 mM | 0.3806 mL | 1.9030 mL | 3.8060 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
 |
|---|
 |
 |
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
COA